This database contains 23 studies, archived under the term: "drug administration schedule"
Click here to filter this large number of results.
Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression
Wang, Lucy Y.,
Shofer, Jane B.,
Rohde, Kirsten,
Hart, Kim L.,
Hoff, David J.,
McFall, Yun H.,
Raskind, Murray A.,
Peskind, Elaine R.
Objectives: Agitation/aggression in Alzheimer disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine (NE) release may contribute to the pathophysiology of agitation/aggression in AD. Prazosin, a nonsedating generic medication used for hypertension and benign prostatic hypertrophy, antagonizes NE effects at brain postsynaptic alpha-1 […]
Long-term effects of rivastigmine capsules in patients with traumatic brain injury
Silver, Jonathan M.,
Koumaras, Barbara,
Meng, Xiangyi,
Potkin, Steven G.,
Reyes, Patricio F.,
Harvey, Philip D.,
Katz, Douglas I.,
Gunay, Ibrahim,
Arciniegas, David B.
Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study.; Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (< or […]
Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer’s disease
Sadowsky, Carl H.,
Dengiz, Alan,
Olin, Jason T.,
Koumaras, Barbara,
Meng, Xiangyi,
Brannan, Stephen
Objective: Evaluate safety and tolerability of switching from donepezil to rivastigmine transdermal patch in patients with mild to moderate Alzheimer’s disease.; Methods: Prospective, parallel-group, open-label study to evaluate immediate or delayed switch from 5-10 mg/day donepezil to 4.6 mg/24 h rivastigmine following a 4-week treatment period.; Results: Rates of discontinuation due to any reason or […]
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, Norman R.,
Szabo, Paul,
Adamiak, Basia,
Burgut, Tuna,
Monthe, Carmen,
Lent, Richard W.,
Younkin, Steven,
Younkin, Linda,
Schiff, Richard,
Weksler, Marc E.
Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer’s disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Abeta). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. […]
Clinical effects of high oral dose of donepezil for patients with Alzheimer’s disease in Japan
Nozawa, Motohiro,
Ichimiya, Yosuke,
Nozawa, Eiko,
Utumi, Yushi,
Sugiyama, Hideki,
Murayama, Norio,
Iseki, Eizo,
Arai, Heii
Background: Donepezil 10 mg/day gained approval in Japan in August 2007 for the treatment of cognitive dysfunction in advanced Alzheimer’s disease.; Methods: We evaluated the efficacy and adverse effects of donepezil when the dose was increased to 10 mg/day in 61 Japanese patients with Alzheimer’s disease. Cognitive function was evaluated using the Revised Hasegawa Dementia […]
Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease
Gehrman, Philip R.,
Connor, Donald J.,
Martin, Jennifer L.,
Shochat, Tamar,
Corey-Bloom, Jody,
Ancoli-Israel, Sonia
Objectives: Patients with Alzheimer dementia often display both agitated behavior and poor sleep. Given that the disease is often associated with low endogenous levels of melatonin, exogenous melatonin administration may lead to improvements in sleep and agitation.; Design: Randomized, placebo-controlled study.; Setting: Nursing homes in San Diego, CA, metropolitan area.; Participants: Subjects were patients with […]
Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep
Many patients with Alzheimer’s disease experience sleep disturbances, and donepezil is usually prescribed for night-time administration. However, increased acetylcholine is associated with cortical arousal. We evaluated whether subjective sleep quality differed according to the timing of medication administration. Ninety-two patients with mild to moderate Alzheimer’s disease who had taken donepezil at night (n=54) or galantamine […]
Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial
Scheltens, Philip,
Kamphuis, Patrick J. G. H.,
Verhey, Frans R.J.,
Olde Rikkert, Marcel G. M.,
Wurtman, Richard J.,
Wilkinson, David,
Twisk, Jos W.R.,
Kurz, Alexander
Objective: To investigate the effect of a medical food on cognitive function in people with mild Alzheimer’s disease (AD).; Methods: A total of 225 drug-naïve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the […]